Actively Recruiting
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Led by Sun Yat-sen University · Updated on 2025-03-13
207
Participants Needed
1
Research Sites
452 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
CONDITIONS
Official Title
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy confirmed extranodal natural killer/T-cell lymphoma, nasal type
- Newly diagnosed stage I or II disease
- At least one evaluable lesion
- ECOG performance status of 0 to 2
- Aged 18 to 75 years
- No other malignancies
- Proper functioning of major organs
You will not qualify if you...
- Hemophagocytic syndrome or aggressive NK cell leukemia
- Involvement of the central nervous system
- Previous treatment with chemotherapy, radiotherapy, immunotherapy, or biotherapy for lymphoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong General Hospital
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
Q
Qingqing Cai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here